Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: Results on local control and survival

Radiotherapy and Oncology

Volumn 100, Issue 2, 2011, Pages 215-220

  Bantema Joppe, Enja J ^a   Van Der Laan, Hans Paul ^a   De Bock, Geertruida H ^a   Wijsman, Robin ^b   Dolsma, Wil V ^a   Busz, Dianne M ^a   Langendijk, Johannes A ^a   Maduro, John H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast conserving therapy; Local control; Radiotherapy; Simultaneous integrated boost; Young

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST CONSERVING THERAPY; BREAST FIBROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; EDEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENCE RISK; RETROSPECTIVE STUDY; RIB FRACTURE; RISK ASSESSMENT; SURVIVAL RATE; TELANGIECTASIA; THORAX PAIN; THREE DIMENSIONAL CONFORMAL SIMULTANEOUS INTEGRATED BOOST IRRADIATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 80052290781     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.05.027     Document Type: Article

References (26)

1. M. Clarke, R. Collins, and S. Darby Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2005 2087 2106 (Pubitemid 41797643)
2. B. Fisher, S. Anderson, and J. Bryant Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer N Engl J Med 347 2002 1233 1241 (Pubitemid 35176242)
3. Landelijke werkgroep behandeling van het mammacarcinoom. Available from: http://www.oncoline.nl/index.php?pagina=/richtlijn/item/pagina.php&id= 27539&richtlijn-id=593. Accessed September 4, 2010.
4. H.P. van der Laan, C.W. Hurkmans, A. Kuten, and H.A. Westenberg Current technological clinical practice in breast radiotherapy; results of a survey in EORTC-Radiation Oncology Group affiliated institutions Radiother Oncol 94 2010 280 285
5. H. Bartelink, J.C. Horiot, and P.M. Poortmans Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial J Clin Oncol 25 2007 3259 3265 (Pubitemid 47325610)
6. H.P. van der Laan, W.V. Dolsma, J.H. Maduro, E.W. Korevaar, M. Hollander, and J.A. Langendijk Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy Int J Radiat Oncol Biol Phys 68 2007 1018 1023 (Pubitemid 47048573)
7. J.J. Jobsen, P.J. van der Palen, and J.H. Meerwaldt The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy Eur J Cancer 37 2001 1820 1827 (Pubitemid 32913307)
8. A.C. Voogd, M. Nielsen, and J.L. Peterse Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials J Clin Oncol 19 2001 1688 1697 (Pubitemid 32230869)
9. P. Zhou, S. Gautam, and A. Recht Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy Breast Cancer Res Treat 101 2007 51 57 (Pubitemid 47555329)
10. G.H. de Bock, J.A. van der Hage, H. Putter, J. Bonnema, H. Bartelink, and V. van de Vijver Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies Eur J Cancer 42 2006 351 356 (Pubitemid 43132890)
11. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181 (Pubitemid 36962641)
12. M.C. Joiner, and A.J. van der Kogel The linear-quadratic approach to fractionation and calculation of isoeffect relationships C.G. Steel, Basic clinical radiobiology 2nd ed. 1997 Arnold London 106 122
13. H. Bartelink, J.C. Horiot, and P. Poortmans Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation N Engl J Med 345 2001 1378 1387
14. M.W. McDonald, K.D. Godette, D.J. Whitaker, L.W. Davis, and P.A. Johnstone Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost Int J Radiat Oncol Biol Phys 77 2010 523 530
15. T. Raiyawa, C. Lertbutsayanukul, and P. Rojpornpradit Late effects and cosmetic results of simultaneous integrated boost versus sequential boost after conventional irradiation in breast-conserving therapy; out come of 7 months follow-up J Med Assoc Thai 92 2009 390 397
16. M.A. Bollet, B. Sigal-Zafrani, and V. Mazeau Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first Radiother Oncol 82 2007 272 280 (Pubitemid 46350796)
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
18. L. Livi, F. Paiar, and C. Saieva Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment Radiother Oncol 82 2007 287 293 (Pubitemid 46350791)
19. K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 2007 1721 1728 (Pubitemid 46668532)
20. P.L. Nguyen, A.G. Taghian, and M.S. Katz Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 2008 2373 2378
21. F.J. Andreu Histologic diagnosis in young women with breast cancer Breast Cancer Res Treat 123 2010 15 18
22. J.H. Kwon, Y.J. Kim, and K.W. Lee Triple negativity, young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less BMC Cancer 10 2010 557
23. T.E. Smith, D. Lee, B.C. Turner, D. Carter, and B.G. Haffty True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management Int J Radiat Oncol Biol Phys 48 2000 1281 1289
24. C.W. Hurkmans, B.C. Cho, E. Damen, L. Zijp, and B.J. Mijnheer Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation Radiother Oncol 62 2002 163 171 (Pubitemid 34286449)
25. C.W. Hurkmans, G.J. Meijer, C. Vliet-Vroegindeweij, M.J. van der Sangen, and J. Cassee High-dose simultaneously integrated breast boost using intensity-modulated radiotherapy and inverse optimization Int J Radiat Oncol Biol Phys 66 2006 923 930 (Pubitemid 44436689)
26. H.P. van der Laan, W.V. Dolsma, and C. Schilstra Limited benefit of inversely optimised intensity modulation in breast conserving radiotherapy with simultaneously integrated boost Radiother Oncol 94 2010 307 312